ArticleCureus2025
Management of Pediatric Post-renal Transplant Erythrocytosis With Enalapril: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post-transplant erythrocytosis (PTE) is a well-documented complication in adult renal transplant recipients but is less commonly reported in pediatric cases. We present an eight-year-old female patient with end-stage renal disease (ESRD) secondary to immune complex-mediated glomerulonephritis, who developed erythrocytosis 10 months after a deceased donor kidney transplant. Despite normal erythropoietin levels and mild obstructive sleep apnea, her hemoglobin (17 g/dL) and hematocrit (52%) remained elevated. She was initially treated with enalapril (2.5 mg daily), leading to hemoglobin normalization, later switched to losartan (titrated to 50 mg daily) for hypertension and proteinuria. Over five years, her hemoglobin has remained within the target range (11.5-14.5 g/dL), with controlled blood pressure and proteinuria. This case highlights the successful long-term management of pediatric PTE with renin-angiotensin system blockade while preserving graft function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.